DOCSLIB.ORG

Baseline CXCL10 and CXCL13 Levels Are Predictive Biomarkers for Tumor Necrosis Factor Inhibitor Therapy in Patients with Moderat

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Baseline CXCL10 and CXCL13 Levels Are Predictive Biomarkers for Tumor Necrosis Factor Inhibitor Therapy in Patients with Moderat Han et al. Arthritis Research & Therapy (2016) 18:93 DOI 10.1186/s13075-016-0995-0 RESEARCH ARTICLE Open Access Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study Bobby Kwanghoon Han1*, Igor Kuzin2, John P. Gaughan3, Nancy J. Olsen4 and Andrea Bottaro2 Abstract Background: TNF inhibitors have been used as a treatment for moderate to severe RA patients. However, reliable biomarkers that predict therapeutic response to TNF inhibitors are lacking. In this study, we investigated whether chemokines may represent useful biomarkers to predict the response to TNF inhibitor therapy in RA. Methods: RA patients (n = 29) who were initiating adalimumab or etanercept were recruited from the rheumatology clinics at Cooper University Hospital. RA patients were evaluated at baseline and 14 weeks after TNF inhibitor therapy, and serum levels of CXCL10, CXCL13, and CCL20 were measured by ELISA. Responders (n = 16) were defined as patients who had good or moderate response at week 14 by EULAR response criteria, and nonresponders (n = 13) were defined as having no response. Results: Responders had higher levels of baseline CXCL10 and CXCL13 compared to nonresponders (p =0.03 and 0.002 respectively). There was no difference in CCL20 levels. CXCL10 and CXCL13 were highly correlated with each other, and were higher in seropositive RA patients. CXCL10 and CXCL13 levels were decreased after TNF inhibitor therapy in responders. Baseline additive levels of CXCL10 + 13 were correlated with changes in DAS score at 14 weeks after TNF inhibitor therapy (r = 0.42, p = 0.03), and ROC curve analyses for predictive ability of CXCL10 + 13 showed an AUC of 0.83. Conclusions: Elevated baseline levels of CXCL10 and CXCL13 wereassociatedwithfavorableresponsetoTNF inhibitor therapy in RA. Subjects with high CXCL10 and high CXCL13 may represent a subset of RA patients whose inflammatory reactions are primarily driven by TNF. Keywords: CXCL10, CXCL13, TNF inhibitor, Rheumatoid arthritis Background for moderate to severe RA patients who have inad- Rheumatoidarthritis(RA)isadiseasethatischarac- equate responses to conventional disease-modifying an- terized by synovial inflammation, cartilage and bone tirheumatic drugs (DMARDs) including methotrexate. destruction, and systemic features [1, 2]. Advances in However, reliable predictive biomarkers of therapeutic understanding the pathogenesis of the disease have response for TNF inhibitor therapy are lacking [3]. fostered the development of new therapeutics. Tumor Several studies have been conducted to discover pre- necrosis factor (TNF) inhibitors are used as a treatment dictive biomarkers for RA therapies. It has been reported that type I interferon (IFN) signature is associated with * Correspondence: [email protected] the therapeutic response to TNF inhibitors and rituximab 1Division of Rheumatology, Cooper Medical School of Rowan University, [4–7]. C-X-C motif chemokine 10 (CXCL10) is induced Camden, NJ 08103, USA by type I and II IFNs [8, 9]. Recruitment and activation of Full list of author information is available at the end of the article © 2016 Han et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Han et al. Arthritis Research & Therapy (2016) 18:93 Page 2 of 7 C-X-C chemokine receptor type 3 (CXCR3)-positive T etanercept treatment). The research protocol was ap- helper 1 (Th1) lymphocytes and monocytes by CXCL10 proved by the Institutional Review Board of Cooper may lead to TNF production in RA [10, 11]. In other University Hospital and all patients provided written in- studies, C-X-C motif chemokine 13 (CXCL13) has been formed consent for participation in the study. reported to be a predictive biomarker for RA therapies [12, 13]. CXCL13, a chemokine that attracts B lympho- Measurement of chemokine levels cytes and follicular helper T lymphocytes (TFH) by bind- Freshly isolated serum samples were aliquoted and stored ing to C-X-C chemokine receptor type 5 (CXCR5), is in a −80 °C freezer until use. Commercial enzyme-linked upregulated in a subset of T cells by TNF or interleukin 6 immunosorbent assay (ELISA) kits were used for serum (IL-6) in RA [14, 15] as well as in follicular dendritic cells measurements of CXCL10 (R&D, Minneapolis, MN, USA), in the germinal center of lymphoid tissues [16]. Lastly, CXCL13 (Sigma-Aldrich, St Louis, MO, USA), and CCL20 baseline interleukin 17 (IL-17) levels are inversely corre- (Sigma-Aldrich, St Louis, MO, USA). lated with response to TNF inhibitor therapy in RA [17]. C-C motif chemokine 20 (CCL20) attracts T helper 17 (Th17) lymphocytes expressing C-C chemokine receptor Statistical analyses type 6 (CCR6), and induced by interleukin 1β (IL-1β), Statistical analyses were performed using SAS v9.4 (SAS IL-17, and TNF [18, 19]. Institute, Cary, NC, USA), and graphs were generated In this study, we investigated whether these three using GraphPad Prism 6.0 (GraphPad Software, La Jolla, chemokines may represent useful predictive biomarkers CA, USA). Continuous variables were compared using for TNF inhibitor therapy in RA patients. We measured Wilcoxon ranked sum test, and dichotomous variables ’ CXCL10, CXCL13, and CCL20 in RA patients who were were compared using Fisher s exact test. Correlations initiating TNF inhibitor therapy and correlated each between pairs of continuous variables were performed chemokine level with the therapeutic response. using Spearman correlation coefficient. Differences be- tween pretreatment and posttreatment chemokine levels Methods were compared using analysis of variance (ANOVA) Patients and assessment for repeated measures. Receiver operating characteris- Patients with RA who met the inclusion and exclusion tic (ROC) curve analysis was performed to assess the criteria were recruited during routine care in the rheuma- predictive ability of cytokine variables. In all the tests, p tology clinics at the Cooper University Hospital (Camden, atwo-sided value <0.05 was considered significant. NJ, USA). The inclusion criteria for this study were: (1) diagnosis of RA by American College of Rheuma- Results tology (ACR) criteria; (2) active RA defined by disease Baseline serum CXCL10 and CXCL13 levels are higher in activity score (DAS) >4.4; (3) inadequate response to responders to TNF inhibitor therapy methotrexate; (4) clinical indication for initiating adalimu- Twenty-nine RA patients who were about to start either mab or etanercept treatment. The exclusion criteria were: adalimumab or etanercept after having an inadequate (1) diagnosis of other connective tissue diseases including response to methotrexate and other DMARDs were systemic lupus erythematosus, systemic sclerosis, or derm- recruited. Five patients had been treated with a TNF atomyositis, or interstitial lung disease; (2) diagnosis of inhibitor previously, and their last treatment was at least chronic infection including viral hepatitis or human 3 months ago. After 14 weeks of TNF inhibitor therapy, immunodeficiency virus; (3) history of malignancy. All using EULAR response criteria, the patients were classi- 29 patients except one were continued on baseline fied into 16 good and moderate responders (collectively methotrexate and other DMARDs while taking adali- termed hereafter as ‘responders’) and 13 nonresponders. mumab (22 patients) or etanercept (7 patients). The pa- Their baseline characteristics, summarized in Table 1, tients were assessed and peripheral blood samples were showed no significant differences between responders obtained at baseline and 14 weeks after TNF inhibitor and nonresponders. therapy. The results of rheumatoid factor (RF), anti- Baseline chemokine levels were measured by ELISA be- cyclic citrullinated peptide antibody (anti-CCP), and fore starting TNF inhibitor therapy and compared between erythrocyte sedimentation rate (ESR) tests were ob- responders and nonresponders (Fig. 1a). Responders had tained as part of patient care. Responders were defined significantly higher serum levels of CXCL10 (606 ± 581 as patients who had good to moderate response at week vs 283 ± 265 pg/ml, p = 0.03) and CXCL13 (383 ± 644 vs 14 by European League Against Rheumatism (EULAR) 27 ± 24 pg/ml, p = 0.002) compared to nonresponders. response criteria (14 with adalimumab and 2 with eta- There was no difference in CCL20 levels between re- nercept treatment), and nonresponders were defined as sponders and nonresponders (14 ± 13 vs 19 ± 31 pg/ml, having no response (8 with adalimumab and 5 with p = 0.78). Han et al. Arthritis Research & Therapy (2016) 18:93 Page 3 of 7 Table 1 Baseline characteristics of RA patients Chemokine levels were compared between seropositive Responders Nonresponders p value and seronegative patients. Baseline CXCL10 and CXCL13 (n = 16) (n = 13) levels were higher in anti-CCP-positive patients than in Age (years) 51.6 ± 12.7 50.7 ± 8.1 0.80a anti-CCP-negative patients (p =0.02 and p = 0.005 re- Gender (female %) 69 (11/16) 77 (10/13) 0.70b spectively). Only baseline CXCL13 levels were higher in p Duration (years) 6.5 ± 4.9 7.4 ± 7.5 0.66a RF-positive patients than in RF-negative patients ( = 0.02) (Table 2). There were no significant differences in RF or anti-CCP positive (%) 75 (12/16) 54 (7/13) 0.27b a posttreatment CXCL10 and CXCL13 levels between RF- DAS28 ESR 6.2 ± 1.1 6.7 ± 0.6 0.15 positive and RF-negative patients (p =0.57 and p =0.72 a ESR (mm) 37 ± 31 30 ± 22 0.79 respectively), and anti-CCP-positive and anti-CCP-negative Values are presented as mean with standard deviation.
Load more

Recommended publications
  • C-X-C Motif Chemokine Ligand 10 Produced by Mouse Sertoli Cells in Response to Mumps Virus Infection Induces Male Germ Cell Apoptosis
    Citation: Cell Death and Disease (2017) 8, e3146; doi:10.1038/cddis.2017.560 OPEN Macmillan Publishers Limited, part of Springer Nature. www.nature.com/cddis Corrected: Correction C-X-C motif chemokine ligand 10 produced by mouse Sertoli cells in response to mumps virus infection induces male germ cell apoptosis Qian Jiang1, Fei Wang1, Lili Shi1, Xiang Zhao1, Maolei Gong1, Weihua Liu1, Chengyi Song2, Qihan Li3, Yongmei Chen1, Han Wu*,1,2 and Daishu Han*,1 Mumps virus (MuV) infection usually results in germ cell degeneration in the testis, which is an etiological factor for male infertility. However, the mechanisms by which MuV infection damages male germ cells remain unclear. The present study showed that C-X-C motif chemokine ligand 10 (CXCL10) is produced by mouse Sertoli cells in response to MuV infection, which induces germ cell apoptosis through the activation of caspase-3. CXC chemokine receptor 3 (CXCR3), a functional receptor of CXCL10, is constitutively expressed in male germ cells. Neutralizing antibodies against CXCR3 and an inhibitor of caspase-3 activation significantly inhibited CXCL10-induced male germ cell apoptosis. Furthermore, the tumor necrosis factor-α (TNF-α) upregulated CXCL10 production in Sertoli cells after MuV infection. The knockout of either CXCL10 or TNF-α reduced germ cell apoptosis in the co-cultures of germ cells and Sertoli cells in response to MuV infection. Local injection of MuV into the testes of mice confirmed the involvement of CXCL10 in germ cell apoptosis in vivo. These results provide novel insights into MuV-induced germ cell apoptosis in the testis.
    [Show full text]
  • CXCL13/CXCR5 Interaction Facilitates VCAM-1-Dependent Migration in Human Osteosarcoma
    International Journal of Molecular Sciences Article CXCL13/CXCR5 Interaction Facilitates VCAM-1-Dependent Migration in Human Osteosarcoma 1, 2,3,4, 5 6 7 Ju-Fang Liu y, Chiang-Wen Lee y, Chih-Yang Lin , Chia-Chia Chao , Tsung-Ming Chang , Chien-Kuo Han 8, Yuan-Li Huang 8, Yi-Chin Fong 9,10,* and Chih-Hsin Tang 8,11,12,* 1 School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei City 11031, Taiwan; [email protected] 2 Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Puzi City, Chiayi County 61363, Taiwan; [email protected] 3 Department of Nursing, Division of Basic Medical Sciences, and Chronic Diseases and Health Promotion Research Center, Chang Gung University of Science and Technology, Puzi City, Chiayi County 61363, Taiwan 4 Research Center for Industry of Human Ecology and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Guishan Dist., Taoyuan City 33303, Taiwan 5 School of Medicine, China Medical University, Taichung 40402, Taiwan; [email protected] 6 Department of Respiratory Therapy, Fu Jen Catholic University, New Taipei City 24205, Taiwan; [email protected] 7 School of Medicine, Institute of Physiology, National Yang-Ming University, Taipei City 11221, Taiwan; [email protected] 8 Department of Biotechnology, College of Health Science, Asia University, Taichung 40402, Taiwan; [email protected] (C.-K.H.); [email protected] (Y.-L.H.) 9 Department of Sports Medicine, College of Health Care, China Medical University, Taichung 40402, Taiwan 10 Department of Orthopedic Surgery, China Medical University Beigang Hospital, Yunlin 65152, Taiwan 11 Department of Pharmacology, School of Medicine, China Medical University, Taichung 40402, Taiwan 12 Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan * Correspondence: [email protected] (Y.-C.F.); [email protected] (C.-H.T.); Tel.: +886-4-2205-2121-7726 (C.-H.T.); Fax: +886-4-2233-3641 (C.-H.T.) These authors contributed equally to this work.
    [Show full text]
  • The Unexpected Role of Lymphotoxin Β Receptor Signaling
    Oncogene (2010) 29, 5006–5018 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The unexpected role of lymphotoxin b receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development MJ Wolf1, GM Seleznik1, N Zeller1,3 and M Heikenwalder1,2 1Department of Pathology, Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland and 2Institute of Virology, Technische Universita¨tMu¨nchen/Helmholtz Zentrum Mu¨nchen, Munich, Germany The cytokines lymphotoxin (LT) a, b and their receptor genesis. Consequently, the inflammatory microenviron- (LTbR) belong to the tumor necrosis factor (TNF) super- ment was added as the seventh hallmark of cancer family, whose founder—TNFa—was initially discovered (Hanahan and Weinberg, 2000; Colotta et al., 2009). due to its tumor necrotizing activity. LTbR signaling This was ultimately the result of more than 100 years of serves pleiotropic functions including the control of research—indeed—the first observation that tumors lymphoid organ development, support of efficient immune often arise at sites of inflammation was initially reported responses against pathogens due to maintenance of intact in the nineteenth century by Virchow (Balkwill and lymphoid structures, induction of tertiary lymphoid organs, Mantovani, 2001). Today, understanding the underlying liver regeneration or control of lipid homeostasis. Signal- mechanisms of why immune cells can be pro- or anti- ing through LTbR comprises the noncanonical/canonical carcinogenic in different types of tumors and which nuclear factor-jB (NF-jB) pathways thus inducing cellular and molecular inflammatory mediators (for chemokine, cytokine or adhesion molecule expression, cell example, macrophages, lymphocytes, chemokines or proliferation and cell survival.
    [Show full text]
  • Defining Natural Antibodies
    PERSPECTIVE published: 26 July 2017 doi: 10.3389/fimmu.2017.00872 Defining Natural Antibodies Nichol E. Holodick1*, Nely Rodríguez-Zhurbenko2 and Ana María Hernández2* 1 Department of Biomedical Sciences, Center for Immunobiology, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States, 2 Natural Antibodies Group, Tumor Immunology Division, Center of Molecular Immunology, Havana, Cuba The traditional definition of natural antibodies (NAbs) states that these antibodies are present prior to the body encountering cognate antigen, providing a first line of defense against infection thereby, allowing time for a specific antibody response to be mounted. The literature has a seemingly common definition of NAbs; however, as our knowledge of antibodies and B cells is refined, re-evaluation of the common definition of NAbs may be required. Defining NAbs becomes important as the function of NAb production is used to define B cell subsets (1) and as these important molecules are shown to play numerous roles in the immune system (Figure 1). Herein, we aim to briefly summarize our current knowledge of NAbs in the context of initiating a discussion within the field of how such an important and multifaceted group of molecules should be defined. Edited by: Keywords: natural antibody, antibodies, natural antibody repertoire, B-1 cells, B cell subsets, B cells Harry W. Schroeder, University of Alabama at Birmingham, United States NATURAL ANTIBODY (NAb) PRODUCING CELLS Reviewed by: Andre M. Vale, Both murine and human NAbs have been discussed in detail since the late 1960s (2, 3); however, Federal University of Rio cells producing NAbs were not identified until 1983 in the murine system (4, 5).
    [Show full text]
  • Mice in Inflammation Psoriasiform Skin IL-22 Is Required for Imiquimod-Induced
    IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice Astrid B. Van Belle, Magali de Heusch, Muriel M. Lemaire, Emilie Hendrickx, Guy Warnier, Kyri This information is current as Dunussi-Joannopoulos, Lynette A. Fouser, Jean-Christophe of September 29, 2021. Renauld and Laure Dumoutier J Immunol published online 30 November 2011 http://www.jimmunol.org/content/early/2011/11/30/jimmun ol.1102224 Downloaded from Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published November 30, 2011, doi:10.4049/jimmunol.1102224 The Journal of Immunology IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice Astrid B. Van Belle,*,† Magali de Heusch,*,† Muriel M. Lemaire,*,† Emilie Hendrickx,*,† Guy Warnier,*,† Kyri Dunussi-Joannopoulos,‡ Lynette A. Fouser,‡ Jean-Christophe Renauld,*,†,1 and Laure Dumoutier*,†,1 Psoriasis is a common chronic autoimmune skin disease of unknown cause that involves dysregulated interplay between immune cells and keratinocytes.
    [Show full text]
  • Critical Role of CXCL4 in the Lung Pathogenesis of Influenza (H1N1) Respiratory Infection
    ARTICLES Critical role of CXCL4 in the lung pathogenesis of influenza (H1N1) respiratory infection L Guo1,3, K Feng1,3, YC Wang1,3, JJ Mei1,2, RT Ning1, HW Zheng1, JJ Wang1, GS Worthen2, X Wang1, J Song1,QHLi1 and LD Liu1 Annual epidemics and unexpected pandemics of influenza are threats to human health. Lung immune and inflammatory responses, such as those induced by respiratory infection influenza virus, determine the outcome of pulmonary pathogenesis. Platelet-derived chemokine (C-X-C motif) ligand 4 (CXCL4) has an immunoregulatory role in inflammatory diseases. Here we show that CXCL4 is associated with pulmonary influenza infection and has a critical role in protecting mice from fatal H1N1 virus respiratory infection. CXCL4 knockout resulted in diminished viral clearance from the lung and decreased lung inflammation during early infection but more severe lung pathology relative to wild-type mice during late infection. Additionally, CXCL4 deficiency decreased leukocyte accumulation in the infected lung with markedly decreased neutrophil infiltration into the lung during early infection and extensive leukocyte, especially lymphocyte accumulation at the late infection stage. Loss of CXCL4 did not affect the activation of adaptive immune T and B lymphocytes during the late stage of lung infection. Further study revealed that CXCL4 deficiency inhibited neutrophil recruitment to the infected mouse lung. Thus the above results identify CXCL4 as a vital immunoregulatory chemokine essential for protecting mice against influenza A virus infection, especially as it affects the development of lung injury and neutrophil mobilization to the inflamed lung. INTRODUCTION necrosis factor (TNF)-a, interleukin (IL)-6, and IL-1b, to exert Influenza A virus (IAV) infections cause respiratory diseases in further antiviral innate immune effects.2 Meanwhile, the innate large populations worldwide every year and result in seasonal immune cells act as antigen-presenting cells and release influenza epidemics and unexpected pandemic.
    [Show full text]
  • The Role of CXCR5 and Its Ligand CXCL13 in The
    European Journal of Endocrinology (2004) 150 225–234 ISSN 0804-4643 EXPERIMENTAL STUDY The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases G Aust, D Sittig, L Becherer1, U Anderegg2, A Schu¨tz3, P Lamesch1 and E Schmu¨cking Institute of Anatomy, 1Department of Surgery, 2Department of Dermatology and 3 Institute of Pathology, University of Leipzig, Leipzig, Germany (Correspondence should be addressed to G Aust, University of Leipzig, Institute of Anatomy, Ph-Rosenthal-Strasse 55, Leipzig, 04103, Germany; Email: [email protected]) Abstract Objective: Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) are characterized by lymphocytic infiltrates partly resembling secondary lymphoid follicles in the thyroid. CXCR5 and its ligand CXCL13 regulate compartmentalization of B- and T-cells in secondary lymphoid organs. The aim of the study was to elucidate the role of this chemokine receptor–ligand pair in thyroid autoimmunity. Methods: Peripheral blood and thyroid-derived lymphocyte subpopulations were examined by flow cyto- metry for CXCR5. CXCR5 and CXCL13 cDNA were quantified in thyroid tissues by real-time RT-PCR. Results: We found no differences between the percentages of peripheral blood CXCR5þ T- and B-cells in GD patients (n ¼ 10) and healthy controls (n ¼ 10). In GD patients, the number of memory CD4þ cells expressing CXCR5 which are functionally characterized as follicular B helper T-cells is higher in thyroid- derived (18^3%) compared with peripheral blood T-lymphocytes (8^2%). The highest CXCL13 mRNA levels were found in HT (n ¼ 2, 86.1^1.2 zmol (10221 mol) cDNA/PCR) followed by GD tissues (n ¼ 16, 9.6^3.5).
    [Show full text]
  • Etters to the Ditor
    LETTERS TO THE EDITOR even in patients with modest or no changes in BM tumor CXCL13 levels are elevated in patients with infiltration, suggesting a contributing mechanism in addi- Waldenström macroglobulinemia, and are tion to tumor debulking.6 Anemia in some WM patients predictive of major response to ibrutinib may be related to elevated hepcidin levels produced by LPL cells.7 However, the effect of ibrutinib on hepcidin Waldenström macroglobulinemia (WM) is character- remains unknown. Serum cytokines are important in ized by bone marrow (BM) infiltration of monoclonal WM biology and can be produced either by the malig- Immunoglobulin M (IgM) secreting lymphoplasmacytic nant cells, the surrounding microenvironmental cells, as lymphoma (LPL), and typically presents with anemia. well as by cells of the immune system.8 The anti-tumor MYD88 and CXCR4 activating somatic mutations effect of ibrutinib may impact all of these compartments, (CXCR4MUT) are common in WM, and found in 90-95% 1–3 including cytokines that may support growth and sur- and 35-40% of WM patients, respectively. Activating vival of tumor cells, and contribute to morbidity in WM, mutations in MYD88 support tumor growth via nuclear 9,10 factor kappa-light-chain enhancer-of-activated B-cells including anemia. As such, we aimed to characterize the serum cytokine profile in WM patients based on (NF-κB), which is triggered by Interleukin (IL)-1 receptor- associated kinases (IRAK4/IRAK1) and Bruton’s tyrosine MYD88 and CXCR4 mutation status, and to characterize kinase (BTK).4 A distinct transcriptome signature based serum cytokine and hepcidin changes in response to ibru- on both MYD88 and CXCR4 mutation status has been tinib therapy.
    [Show full text]
  • Metamorphic Protein Folding Encodes Multiple Anti-Candida Mechanisms in XCL1
    pathogens Article Metamorphic Protein Folding Encodes Multiple Anti-Candida Mechanisms in XCL1 Acacia F. Dishman 1,2,†, Jie He 3,†, Brian F. Volkman 1,* and Anna R. Huppler 3,* 1 Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA; [email protected] 2 Medical Scientist Training Program, Medical College of Wisconsin, Milwaukee, WI 53226, USA 3 Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA; [email protected] * Correspondence: [email protected] (B.F.V.); [email protected] (A.R.H.) † These authors contributed equally. Abstract: Candida species cause serious infections requiring prolonged and sometimes toxic therapy. Antimicrobial proteins, such as chemokines, hold great interest as potential additions to the small number of available antifungal drugs. Metamorphic proteins reversibly switch between multiple different folded structures. XCL1 is a metamorphic, antimicrobial chemokine that interconverts between the conserved chemokine fold (an α–β monomer) and an alternate fold (an all-β dimer). Previous work has shown that human XCL1 kills C. albicans but has not assessed whether one or both XCL1 folds perform this activity. Here, we use structurally locked engineered XCL1 variants and Candida killing assays, adenylate kinase release assays, and propidium iodide uptake assays to demonstrate that both XCL1 folds kill Candida, but they do so via different mechanisms. Our results suggest that the alternate fold kills via membrane disruption, consistent with previous work, and the chemokine fold does not. XCL1 fold-switching thus provides a mechanism to regulate Citation: Dishman, A.F.; He, J.; the XCL1 mode of antifungal killing, which could protect surrounding tissue from damage associ- Volkman, B.F.; Huppler, A.R.
    [Show full text]
  • And B Cell-Associated Cytokine And
    Gyllemark et al. Journal of Neuroinflammation (2017) 14:27 DOI 10.1186/s12974-017-0789-6 RESEARCH Open Access Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study Paula Gyllemark1* , Pia Forsberg2, Jan Ernerudh3 and Anna J. Henningsson4 Abstract Background: B cell immunity, including the chemokine CXCL13, has an established role in Lyme neuroborreliosis, and also, T helper (Th) 17 immunity, including IL-17A, has recently been implicated. Methods: We analysed a set of cytokines and chemokines associated with B cell and Th17 immunity in cerebrospinal fluid and serum from clinically well-characterized patients with definite Lyme neuroborreliosis (group 1, n = 49), defined by both cerebrospinal fluid pleocytosis and Borrelia-specific antibodies in cerebrospinal fluid and from two groups with possible Lyme neuroborreliosis, showing either pleocytosis (group 2, n = 14) or Borrelia-specific antibodies in cerebrospinal fluid (group 3, n = 14). A non-Lyme neuroborreliosis reference group consisted of 88 patients lacking pleocytosis and Borrelia-specific antibodies in serum and cerebrospinal fluid. Results: Cerebrospinal fluid levels of B cell-associated markers (CXCL13, APRIL and BAFF) were significantly elevated in groups 1, 2 and 3 compared with the reference group, except for BAFF, which was not elevated in group 3. Regarding Th17-associated markers (IL-17A, CXCL1 and CCL20), CCL20 in cerebrospinal fluid was significantly elevated in groups 1, 2 and 3 compared with the reference group, while IL-17A and CXCL1 were elevated in group 1. Patients with time of recovery <3 months had lower cerebrospinal fluid levels of IL-17A, APRIL and BAFF compared to patients with recovery >3 months.
    [Show full text]
  • Ncomms1239.Pdf
    ARTICLE Received 10 Nov 2010 | Accepted 15 Feb 2011 | Published 15 Mar 2011 DOI: 10.1038/ncomms1239 Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer Ole Audun Werner Haabeth1, Kristina Berg Lorvik1, Clara Hammarström2, Ian M. Donaldson3,4, Guttorm Haraldsen2, Bjarne Bogen1 & Alexandre Corthay1 The immune system can both promote and suppress cancer. Chronic inflammation and proinflammatory cytokines such as interleukin (IL)-1 and IL-6 are considered to be tumour promoting. In contrast, the exact nature of protective antitumour immunity remains obscure. Here, we quantify locally secreted cytokines during primary immune responses against myeloma and B-cell lymphoma in mice. Strikingly, successful cancer immunosurveillance mediated by tumour-specific CD4 + T cells is consistently associated with elevated local levels of both proinflammatory (IL-1α, IL-1β and IL-6) and T helper 1 (Th1)-associated cytokines (interferon-γ (IFN-γ), IL-2 and IL-12). Cancer eradication is achieved by a collaboration between tumour- specific Th1 cells and tumour-infiltrating, antigen-presenting macrophages. Th1 cells induce secretion of IL-1β and IL-6 by macrophages. Th1-derived IFN-γ is shown to render macrophages directly cytotoxic to cancer cells, and to induce macrophages to secrete the angiostatic chemokines CXCL9/MIG and CXCL10/IP-10. Thus, inflammation, when driven by tumour- specific Th1 cells, may prevent rather than promote cancer. 1 Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, Norway. 2 Department of Pathology, Institute of Pathology, Oslo University Hospital Rikshospitalet and University of Oslo, PO Box 4950 Nydalen, 0424 Oslo, Norway.
    [Show full text]
  • CCL20/CCR6 Signaling Regulates Bone Mass Accrual in Mice
    ORIGINAL ARTICLE JBMR CCL20/CCR6 Signaling Regulates Bone Mass Accrual in Mice Michele Doucet, Swaathi Jayaraman, Emily Swenson, Brittany Tusing, Kristy L Weber,Ã and Scott L Kominsky Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA ABSTRACT CCL20 is a member of the macrophage inflammatory protein family and is reported to signal monogamously through the receptor CCR6. Although studies have identified the genomic locations of both Ccl20 and Ccr6 as regions important for bone quality, the role of CCL20/CCR6 signaling in regulating bone mass is unknown. By micro–computed tomography (mCT) and histomorphometric analysis, we show that global loss of Ccr6 in mice significantly decreases trabecular bone mass coincident with reduced osteoblast numbers. Notably, CCL20 and CCR6 were co-expressed in osteoblast progenitors and levels increased during osteoblast differentiation, indicating the potential of CCL20/CCR6 signaling to influence osteoblasts through both autocrine and paracrine actions. With respect to autocrine effects, CCR6 was found to act as a functional G protein–coupled receptor in osteoblasts and although its loss did not appear to affect the number or proliferation rate of osteoblast progenitors, differentiation was significantly inhibited as evidenced by delays in osteoblast marker gene expression, alkaline phosphatase activity, and mineralization. In addition, CCL20 promoted osteoblast survival concordant with activation of the PI3K-AKT pathway. Beyond these potential autocrine effects, osteoblast-derived CCL20 stimulated the recruitment of macrophages and T cells, known facilitators of osteoblast differentiation and survival. Finally, we generated mice harboring a global deletion of Ccl20 and found that Ccl20-/- mice exhibit a reduction in bone mass similar to that observed in Ccr6-/- mice, confirming that this phenomenon is regulated by CCL20 rather than alternate CCR6 ligands.
    [Show full text]